{"id":"NCT01707290","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation","officialTitle":"A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2016-04","completion":"2016-04","firstPosted":"2012-10-16","resultsPosted":"2017-05-12","lastUpdate":"2017-05-12"},"enrollment":125,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Ivacaftor","otherNames":["Kalydeco","VX-770"]}],"arms":[{"label":"Ivacaftor","type":"EXPERIMENTAL"},{"label":"Observational","type":"NO_INTERVENTION"}],"summary":"The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm","timeFrame":"Day 1 up to Week 108 (Study 112)","effectByArm":[{"arm":"Ivacaftor Arm","deltaMin":117,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":38,"countries":["United States","Belgium","France","United Kingdom"]},"refs":{"pmids":["32965659","26070913"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":121},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Cough","Headache","Sinus congestion","Sputum increased"]}}